UPDATE - Barclays upgraded NuVasive (NASDAQ: NUVA) from Equalweight to Overweight, price target cut from $32 to $25.

Analyst Matthew ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE